ORIGINAL RESEARCH

Characteristics and prognosis of synchronous multiple primary lung cancer after surgical treatment: A systematic review and meta-analysis of current evidence

Hongtao Tie1 | Jun Luo1 | Rui Shi2,3 | Zhenhan Li4 | Dan Chen1 | Qingchen Wu1

1Department of Cardiothoracic Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
2Service de Médecine Intensive – Réanimation, Hôpital Bicêtre, AP-HP, Université Paris-Saclay, Saint-Aubin, France
3INSERM UMR_S999 LabEx - LERMIT, Hôpital Marie-Lannelongue, Le Plessis Robinson, France
4Chongqing Medical University, Chongqing, China

Abstract

Background: This study aims to quantitatively summary the characteristics of synchronous multiple primary lung cancer (sMPLC), postoperative mortality, long-term prognosis, and prognostic effects of potential clinical parameters in patients with sMPLC after surgery.

Methods: PubMed and Embase databases were systematically searched to identify studies that explored the prognosis of patients with sMPLC after surgery.

Results: Fifty-two studies with 3486 participants were included, and clinical characteristics were quantitatively summarized. The pooled proportion of sMPLC in lung cancer was 2.0% (95%CI, 1.6%–2.5%) with an increasing trend over time, and postoperative mortality was 1.4% (95%CI, 0.5%–2.7%) with a decreasing trend over time. The 5-year survival rate was 44.9% (95%CI, 37.4%–52.6%) and all long-term survival rates showed increasing trends over time. Poor long-term prognosis was observed in both limited resection (HR = 1.357, 95%CI, 1.047–1.759, p = 0.0210) and pneumonectomy (HR = 2.643, 95%CI, 1.539–4.541, p = 0.0004) by comparison of anatomical resection. Other clinical parameters of age, gender, smoking status, FEV1, and lymph node metastasis significantly impacted the long-term prognosis (all p < 0.05).

Conclusions: The proportion of sMPLC in lung cancer and 5-year survival rate are increasing, while postoperative mortality is decreasing trend over time. Lobectomy should be preferred, while pneumonectomy should be avoided for sMPLC. Age, gender, FEV1, smoking, tumor size, surgical methods, and lymph node status are prognostic factors for sMPLC. Considering the heterogeneity and publication bias, these findings should be treated with caution.

KEYWORDS
prognosis, surgical treatment, synchronous multiple primary lung cancer, systematic review and meta-analysis
1 | INTRODUCTION

Synchronous multiple primary lung cancer (sMPLC) is a special type of lung cancer, characterized by at least two primary tumors simultaneously identified in ipsilateral or contralateral lung. SMPLC was first reported by Beyreuther in 1924, with a wide great range of reported proportion from 0.2% to 6.2% in lung cancer. With improved imaging techniques, particularly high-resolution chest computed tomography (CT), and positron emission tomography, increasing number of patients with synchronous multiple lung nodules are being diagnosed, which of these nodules could be sMPLC or pulmonary metastasis from the lung or other tumor. According to the current conception, surgical resection has been advocated for patients with certain sMPLC, but not pulmonary metastasis for no favorable survival from surgical resection. However, it is not always possible to know the suspicious lung nodules to be sMPLC or pulmonary metastasis preoperatively, and the operative outcome after surgery remains unclear.

With the accumulating concerns on sMPLC, the American Joint Committee on Cancer (AJCC) seventh edition of the cancer tumor-node-metastasis (TNM) staging system defined the additional tumor nodules in different location with a disparate stage. In detail, nodules in the same lobe were staged as T3M0, multiple ipsilateral lobes as T4M0, and contralateral lobes as M1A. However, this classification schema could not reliably predict the prognosis of patients with sMPLC because these it based upon the supposition that multiple lung nodules are intrapulmonary metastases originated from the primary lung cancer, rather than sMPLC. The prognostic appropriateness of such a categorization necessitates further evaluation. Additionally, special features of tumor size, number of tumors, and histology between tumors in sMPLC were not considered in this staging system.

As reported in the current literature, the overall prognosis of patients with sMPLC after surgery differed broadly from each other, and the prognostic effect of various clinical parameters was inconsistent. The shortage of proper staging system and lack of statistical overall survival (OS) of sMPLC might ascribe to its rare occurrence. With the increasing concern and accumulating evidence, but little knowledge and considerable controversy about sMPLC, we performed current systematic review and meta-analysis of current evidence to investigate the characteristics of sMPLC and postoperative mortality. Additionally, the prognosis after surgical treatment and prognostic effects of various potential clinical parameters in patients with sMPLC was explored.

2 | MATERIALS AND METHODS

The protocol of the current study was registered in an international database of PROSPERO (http://www.crd.york.ac.uk/PROSPERO/), with a registered ID: CRD42018099789. We performed and reported the study following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and Meta-analyses and Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines. Since all analyses are based on previous published studies, no ethical approval and patient consent are required.

2.1 | Literature search

We conducted a systematical literature search in PubMed and Embase (from the inception to Oct 2019). The search strategy was performed by two investigators independently, and the detailed search strategy is in Data S1. In addition to database retrieval, references list of the retrieved studies, and review articles were also screened, and the process was performed repeatedly until no further eligible studies included. Conference abstracts and non-English studies eligible for inclusion were also included.

2.2 | Study selection and criteria

The detailed study selection was achieved through two steps. First, we screened the titles and abstracts as the preliminary selection, and then, read the full texts strictly accord to the criteria. Study selection was performed by two investigators independently, and the discrepancies were indicated and solved by another superior investigator. Eligible studies must meet the following criteria: (a) patients with sMPLC; (b) surgery for the treatment of sMPLC; (c) available survival data for sMPLC. When research with the same population has multiple publications, only the completed and recent one was included. Exclusion criteria: (a) only medicine therapy for patients with sMPLC; (b) unavailable prognostic data; (c) patient with intrapulmonary metastasis.

2.3 | Data extraction and quality assessment

The following information was extracted in a standard extraction form: first author, year of publication, period of participant enrollment, study area, number of patients with sMPLC, number of patients with lung cancer, gender, age, lesions location, number of lesions, identical histology, surgery type, postoperative mortality, and survival rate. Patients’ characteristics (gender, age, FEV1, smoking status, lesions location, number of lesions, histology, surgery type, lymph metastasis, and adjunctive therapy) with corresponding 5-year survival rate and hazard ratios (HRs) for OS and 95%CIs were extracted as a separate standard form. Survival rate and HRs and 95%CIs from studies concealing
results in Kaplan–Meier curves were estimated by software of GetData.Graph.Digitizer.v2.24 (http://getdata-graph-digitizer.com/). If some essential data were unavailable, the corresponding authors would be contacted.

The risk of bias in each study was assessed using the modified Newcastle–Ottawa quality scale59,60 (Data S1) to fit our included studies, with a maximum of 7 points. The higher scores mean lower risk of bias, and studies were evaluated as high quality (6–7 stars).

2.4 | Data analysis

In order to present trends over time, bubble charts were applied to describe the distribution between publication year and the corresponding proportion of sMPLC in lung cancer, postoperative mortality rate, and survival rates of sMPLC. Every bubble represents one study, and publication year is for X-axis, Y-axis for the corresponding rate, and the area of the bubble for corresponding sample size. Bubble charts were performed with OriginPro 9.1 (OriginLab Corporation). Additionally, correlation relationships between publication years and the rates were analyzed by Spearman’s rank correlation in R software.

Events and totals were used to perform the meta-analysis for the proportion of sMPLC in lung cancer, postoperative mortality, proportions of female, three or more tumors, unilateral lung, and same histology in sMPLC, and means with standard deviations were used for age. Both survival rates and HRs with 95% CIs were used for prognosis analysis. For pooling survival rates, we presumed that no loss to follow up occurred in all included studies, and the events of survival could be calculated by total patients multiplying the corresponding survival rate. All meta-analyses were performed by using random-effects models. For proportion, postoperative mortality, and survival rates, meta-analysis was conducted by Freeman–Tukey double arc sine transformation arcsine61 in R software with package meta and metaprop. Log-transform and R software with package meta and metagen were used for meta-analysis of HRs with 95% CIs.

Heterogeneity among the studies was assessed by $I^2$ statistic, which represents the percentage of variation attributed to heterogeneity instead of chance error.62 Subgroup analysis was performed for the proportion of sMPLC, postoperative mortality, and 5-year OS rate. Sensitivity analysis by omitting one study in each turn was also performed. Predesigned additional analyses for 5-year survival rate and effect sizes of HRs with 95% CIs were performed to explore the prognostic role of the clinical parameters: Age (older vs. young), gender (female vs. male), smoke status (smoker vs. nonsmoker), FEV1 (high vs. low), numbers of tumors (more than two tumors vs. two tumors), location (unilateral vs. bilateral), surgical methods (anatomical vs. limited vs. pneumonectomy), gender ratio was 36.7%; the average age was 63.35 years; the proportion of tumors with identical histology was 63.0%; the proportion of more than two tumors was 15.4%; the proportion of female, three or more tumors, unilateral lung, and same histology in sMPLC, and means with standard deviations were used for age. Both survival rates and HRs with 95% CIs were used for prognosis analysis. For pooling survival rates, we presumed that no loss to follow up occurred in all included studies, and the events of survival could be calculated by total patients multiplying the corresponding survival rate. All meta-analyses were performed by using random-effects models. For proportion, postoperative mortality, and survival rates, meta-analysis was conducted by Freeman–Tukey double arc sine transformation arcsine61 in R software with package meta and metaprop. Log-transform and R software with package meta and metagen were used for meta-analysis of HRs with 95% CIs.

Heterogeneity among the studies was assessed by $I^2$ statistic, which represents the percentage of variation attributed to heterogeneity instead of chance error.62 Subgroup analysis was performed for the proportion of sMPLC, postoperative mortality, and 5-year OS rate. Sensitivity analysis by omitting one study in each turn was also performed. Predesigned additional analyses for 5-year survival rate and effect sizes of HRs with 95% CIs were performed to explore the prognostic role of the clinical parameters: Age (older vs. young), gender (female vs. male), smoke status (smoker vs. nonsmoker), FEV1 (high vs. low), numbers of tumors (more than two tumors vs. two tumors), location (unilateral vs. bilateral), surgical methods (anatomical vs. limited vs. pneumonectomy), tumor histology (same vs. different), lymph node metastasis (yes vs. no), and postoperative adjunctive therapy (yes vs. no).

Publication bias was assessed with Funnel plots and Egger’s test.63 All statistical analyses were performed by using R, version 3.4.0, and two-tailed $p$-values less than 0.05 was as statistically significant.

3 | RESULTS

3.1 | Characteristics of eligible studies

The flow chart of the detailed selection process is presented in Figure 1 and the basic characteristics of included studies are summarized in Table 1. The literature search yielded 2897 records and 52 studies were included. Tumor location, outcomes of postoperative mortality, survival rates, and HRs with 95% CIs and 5-year survival rate regarding various clinical parameters displayed in Data S1. All included studies were longitudinal studies. They were published between 1987 and 2018, and sample sizes of sMPLC ranged from 8 to 438, with a total of 3486. For characteristic analysis, 38 studies with 2678 patients reported the gender ratio, 37 studies with 2604 patients reported the ages, 28 studies with 2169 patients reported the proportion of more than two tumors, 44 studies with 2819 patients reported the tumor location, and 44 studies with 3159 patients reported the proportion of identical histology. Most studies were adjudicated to be of high quality with a score of more than 5 (Data S1).

3.2 | Characteristics of the patients with sMPLC

The detailed pooled effect size of characteristics in patients with sMPLC is summarized in Table 2. Meta-analysis with random-effects model showed that, in sMPLC, the female gender ratio was 36.7%; the average age was 63.35 years; the proportion of more than two tumors was 15.4%; the proportion of tumors located in the unilateral lung was 62.4%; the proportion of tumors with identical histology was 63.0%.

3.3 | Proportion of sMPLC in lung cancer

Thirty-nine studies, including 2215 sMPLC patients diagnosed from 122,000 patients with primary lung cancer undergoing surgical resection, were used to calculate the proportion of sMPLC, and the pooled result was 2.0% (95% CI, 1.6%–2.5%, Table 2), with significant evidence of between-study heterogeneity ($I^2 = 97$%). Sensitivity analysis by omitting each study in turn revealed that the proportion of sMPLC...
in LC remained consistently, ranged from 1.9% to 2.1%. The
distribution between publication year and the corresponding
proportion of sMPLC revealed an increasing trend by visual
inspection and a significant positive correlation Spearman
analysis (Figure 2A, \( r = 0.349, p = 0.029 \)). Subgroup analy-
sis according to publication year showed the proportion of
sMPLC was 1.7% (95%CI, 1.1%–2.3%) before 2010 and
2.5% (95%CI, 1.8%–3.2%) after 2010, with an almost signifi-
cant difference (Figure 3A, \( p = 0.077 \)).

### 3.4 | Postoperative mortality

Meta-analysis of 42 studies, including 68 deaths from 2505
sMPLC patients, showed that the postoperative mortality was
1.4% (95%CI, 0.5%–2.7%, \( I^2 = 64\% \), Table 2 and Data S1). Sensitivity analysis by omitting each study in turn showed
that postoperative mortality ranged from 1.1% to 1.6%. A
decreased trend of postoperative mortality over time was
observed in the bubble charts, with a nonsignificant nega-
tive correlation (Figure 2B, \( r = -0.259, p = 0.097 \)). While a
significant difference between postoperative mortality before
and after 2010 [2.9% (95%CI, 1.2%–5.2%) vs. 0.7% (95%CI,
0.0%–1.8%)] was detected in subgroup analysis (Figure 3A,
\( p = 0.0048 \)).

### 3.5 | Survival rate of sMPLC

The overall results demonstrated the 1-, 2-, 3-, and 5-year survival rates were 86.8% (95%CI, 81.9%–91.2%, \( I^2 = 85\% \))
by pooling 37 studies with 1682 participants, 71.7% (95%CI,
63.6%–79.1%, \( I^2 = 91\% \)) by pooling 34 studies with 1624
participants, 62.9% (95%CI, 54.3%–71.2%, \( I^2 = 93\% \))
by pooling 39 studies with 2085 participants, and 44.9%
(95%CI, 37.4%–52.6%, \( I^2 = 94\% \)) by pooling 48 studies with
3217 participants (Table 2 and Data S1). Sensitivity analy-
sis by omitting each study in turn revealed that the 5-year survival rates ranged from 43.7% to 46.2%, respectively.
Increased trends of 1-, 2-, 3-, and 5-year survival rates over
time and significant positive correlations were observed
(Figure 2C–F, \( r = 0.629, 0.700, 0.660, 0.680 \), respectively,
| Study ID   | Recruitment time | Area    | SMPLC/LC | Female/Male | Age (years) | Three or more tumors | Identical histology |
|-----------|-----------------|---------|----------|-------------|-------------|-----------------------|---------------------|
| Adebonojo 1997 | 1984–1995 | USA     | 15/1325 | NA          | NA          | NA                    | 3/15                |
| Andriolo 2012  | 2000–2010 | Italy   | 13/NA   | NA          | NA          | NA                    | NA                  |
| Angeletti 1995  | 1980–1993 | Italy   | 18/1960 | 0/18        | 62.3 ± 6.84 | NA                    | 6/18                |
| Antakli 1995    | 1966–1994 | USA     | 26/1572 | NA          | NA          | 6/26                  | NA                  |
| Aziz 2002       | 1985–1999 | UK      | 10/892  | 2/8         | 54 ± 6.1    | NA                    | 7/10                |
| Bae 2012        | 1990–2008 | Korea   | 19/1852 | 6/13        | 60.8 ± 7.69 | NA                    | 8/19                |
| Chang 2007      | 1990–2006 | Taiwan  | 92/1651 | 40/52       | 64 (37–83)  | 54/92                | 89/92               |
| Chen 2015       | 2007–2014 | China   | 108/1868 | 69/34       | 60 ± 10     | 14/103               | 97/103              |
| Cheng 2017      | 2007–2012 | China   | 45/2138 | NA          | NA          | NA                    | 0/45                |
| De Leyn 2008    | 1990–2007 | Belgium | 57/3399 | 7/29        | 64.5 (37–80) | NA                   | 18/36               |
| Deschamps 1990  | NA    | USA     | 36/NA   | NA          | NA          | NA                    | NA                  |
| Fabian 2011     | 1996–2009 | USA     | 67/NA   | 37/30       | 70.9 ± 8.7  | NA                    | 29/67               |
| Feng 2005       | 1983–2004 | China   | 31/4649 | 12/19       | 63 (32–83)  | NA                    | 9/31                |
| Finley 2010     | 1995–2006 | USA     | 175/NA  | 108/67      | 69 (42–87)  | 50/175                | 146/175             |
| Guo 2017        | 2010–2015 | China   | 357/25339 | 248/109    | 60 (28–80)  | 88/357                | 331/357             |
| Hardavella 2018 | 2013–2017 | Greece  | 8/NA    | 3/5         | 65 (49–58)  | NA                    | NA                  |
| Hsu 2016        | 2006–2012 | China   | 35/564  | 24/11       | 65 (49–82)  | 9/35                  | NA                  |
| Ishikawa 2014   | 1995–2009 | Japan   | 93/2041 | 57/36       | 68 (49–84)  | 22/93                 | NA                  |
| Jung 2011       | 1995–2008 | South Korea | 32/4286 | 10/22       | 65 (30–77)  | 3/32                  | 14/32               |
| Kocaturk 2011   | 2001–2008 | Taiwan  | 26/1355 | 0/26        | 59.6 (48–77) | 2/26                | 17/26               |
| Li 2011         | 1999–2009 | China   | 72/NA   | 18/54       | 66 (37–79)  | NA                    | 33/72               |
| Li 2017         | 2009–2011 | China   | 36/1948 | 14/22       | 59.7 ± 9.6  | NA                    | 33/36               |
| Lin 2014        | 2005–2012 | Taiwan  | 64/1223 | 46/18       | 60 (27–81)  | 11/64                 | 64/64               |
| Liu 2016        | 1990–2010 | China   | 122/13587 | 68/54      | 61.5 ± 7.6  | 21/122               | 88/122              |
| Liu 2017        | NA     | China   | 438/NA  | NA          | NA          | NA                    | 339/438             |
| lv 2018         | 2010–2016 | China   | 48/3031 | NA          | NA          | NA                    | NA                  |
| Mun 2007        | 1999–2004 | Japan   | 19/674  | 13/6        | 65.8 (52–80) | 12/19               | 10/19               |
| Okada 1998      | 1985–1996 | Japan   | 28/908  | 4/24        | 64.3 ± 7.7  | NA                    | 12/28               |
| Peng 2017       | 2012–2016 | China   | 43/NA   | 26/17       | 58 (39–76)  | 9/43                 | 38/43               |
| Pommier 1996    | 1974–1994 | USA     | 27/3034 | 1/26        | 63 (17–78)  | NA                    | 15/27               |
| Rea 2001        | 1971–1999 | Italy   | 19/NA   | NA          | NA          | NA                    | 13/19               |
| Ribet 1995      | 1971–1990 | France  | 24/1980 | 0/24        | 57 (40–70)  | 0/24                 | 14/24               |
| Riquet 2008     | 1983–2005 | France  | 118/3427 | 26/92      | 63.2 ± 10   | 14/118               | 60/118              |
| Rosengart 1991  | 1955–1990 | USA     | 33/NA   | NA          | 63          | 0/33                 | 16/33               |
| Rostad 2008     | 1993–2000 | Norway  | 94/2528 | 40/54       | 64 (41–83)  | 28/94                | 85/94               |
| Shah 2012       | 1997–2010 | USA     | 47/NA   | 24/23       | 66 ± 9     | NA                    | 30/47               |
| Takamochi 2012  | 1996–2008 | Japan   | 31/1047 | 17/14       | 65.8 ± 9.0  | 7/31                 | 13/31               |
| Tanvetyanon 2010 | 1997–2008 | USA     | 116/2582 | 69/47      | 70 (45–86)  | NA                    | 80/116              |
| Troussse 2007   | 1985–2006 | France  | 125/2785 | 27/98      | 61.5 ± 9.9  | 2/125                | 104/125             |
| Tsunezuka 2004  | 1973–2001 | Japan   | 19/1906 | NA          | 70 (51–82)  | NA                    | 10/19               |
| Tung 2003       | 1983–2001 | Taiwan  | 20/1406 | 9/11        | 66.4 ± 10.6 | 3/20                 | 20/20               |
| van Rens 2000   | 1970–1997 | Netherlands | 85/3372 | 9/76      | 65.8        | NA                    | 50/73               |
| Vansteenkiste 2001 | 1990–1994 | Belgium | 35/NA   | NA          | NA         | 0/35                 | 30/35               |

(Continues)
and all \( p < 0.001 \). Additionally, there is a significant difference between 5-year survival rate before and after 2010 (28.2% (95% CI, 21.8%–35.0%) vs. 62.5% (95% CI, 54.4%–70.3%), Figure 3A, \( p < 0.0001 \)).

### 3.6 Effect of various clinical parameters on 5-year survival rate

Additional analyses were performed to evaluate the effects of various clinical parameters on the 5-year survival rate. The forest chart of all subgroup analyses is shown in Data S1. As shown in Figure 3B, female, never smoker, and high FEV1 were associated with a significantly increased 5-year survival rate (All \( p < 0.05 \)). As mandatory parameters of TNM classification, a better 5-year survival rate was observed to be significant in patients without lymph node metastasis (\( p = 0.003 \)) and extremely close to significance in patients with the largest tumor size \( \leq 3 \) cm (\( p = 0.068 \)). While no significant impact on 5-year survival rate was observed in clinical parameters.

### 3.7 Effect of various clinical parameters on OS

Additional analyses by meta-analyses of HRs with 95% CIs were also executed to assess the effect of various clinical parameters on OS, shown in Figure 4 and Data S1. Consistent with 5-year survival rate, gender, smoking status, largest tumor size, and lymph node metastasis status have significant impacts on OS, and no significant association between OS and parameters of tumors numbers, tumor location, tumor histology, postoperative adjunctive therapy. Though inconsistency between statistical significance existed in FEV1, age and surgical methods analysis, the trends were consistent. High FEV1 showed a better OS with a slight tendency toward significance [HR = 0.597 (95% CI, 0.305–1.169), \( p = 0.1323 \)]. While for age analysis, the difference of OS between older and young patients reached a statistical significance (HR = 1.895, 95% CI, 1.405–2.557, \( p < 0.0001 \)). For surgical method in sMPLC, limited resection showed a statistically significant worse OS than anatomical resection (HR = 1.357, 95% CI, 1.045–1.759, \( p = 0.021 \)). Pneumonectomy was significantly associated with worse OS by comparison of non-pneumonectomy (HR = 2.643, 95% CI, 1.539–4.541, \( p = 0.0004 \)).

### 3.8 Publication bias

Asymmetry with smaller studies yielding more extreme estimates were observed in all funnel plots (Data S1) by visual inspection, and evidence of publication bias were also detected by the Egger's test for the proportion of sMPLC (\( p = 0.011 \)), postoperative mortality (\( p = 0.044 \)), and 5-years survival rate (\( p = 0.001 \)).

### 4 DISCUSSION

This is the first systematic review and meta-analysis focusing characteristics and prognosis after surgical treatment of sMPLC, with 52 studies involving 3486 sMPLC. The main findings are: (a) The proportion of sMPLC is 2.0% of the lung cancer population with a significantly increasing trend over time, while the postoperative mortality is decreasing over time, with a pooled incidence of 1.4%. (b) The pooled 1-, 2-, 3-, and 5-year survival rates were 86.8%, 71.7%, 62.9%, and 44.9%, with significant increasing trends over time. (c) Age, gender, FEV1, smoking status, tumor size, surgical methods, and lymph node status are important prognostic factors for patients with sMPLC after surgery. In this study, we gave an overview of characteristics, prognosis, and prognostic factors.
of sMPLC after surgery, with expected substantial heterogeneity and evidence of publication bias among included studies.

With the establishment of the lung cancer screening program and improvement of screening techniques, it has been reported that patients diagnosed with sMPLC are increasing

| Clinical data                          | Studies involved | N involved | Pooled results | I2   |
|---------------------------------------|-----------------|------------|----------------|------|
| ALL-included sMPLC patients           | 52              | 3486       | "/>            | "/>  |
| Percentage of sMPLC/LC                | 39              | 2215/12200 | 0.020 [0.016 to 0.025] | 97%  |
| Synchronous MPLC LC                   | 39              | 2215       | 12200          |      |
| Synchronous MPLC from unknown LC      | 13              | 1271/NA    |                |      |
| Gender analysis (Percentage of female) | 38              | 1275/2678  | 0.367 [0.293 to 0.444] | 93%  |
| Female                                | 38              | 1275       |                |      |
| Male                                  | 1403            |            |                |      |
| Not reported                          | 14              | 808        |                |      |
| Age analysis                          | 37              | 2604       | 63.35 [60.65 to 66.05] | 0%   |
| Percentage of three or more tumors    | 27              | 426/2169   | 0.154 [0.107 to 0.208] | 89%  |
| Three or more tumors                  | 27              | 426        |                |      |
| Two tumors                            | 1743            |            |                |      |
| Not reported                          | 25              | 1284       |                |      |
| Location (Percentage of unilateral)   | 44              | 1860/2819  | 0.624 [0.548 to 0.697] | 93%  |
| Same lobe                             | 26              | 660        |                |      |
| Unilateral different lobes            | 26              | 872        |                |      |
| Unilateral                            | 14              | 328        |                |      |
| Bilateral                             | 43              | 959        |                |      |
| Not reported                          | 8               | 634        |                |      |
| Histology (Percentage of same)        | 44              | 2295/3159  | 0.630 [0.547; 0.710] | 95%  |
| Same                                  | 44              | 2295       |                |      |
| Different                             | 864             |            |                |      |
| Not reported                          | 8               | 294        |                |      |
| Prognosis analysis                    | 52              | 3432       |                |      |
| Postoperative mortality               | 42              | 68/2505    | 0.014 [0.005 to 0.027] | 64%  |
| 1-year survival rate                  | 37              | 1682       | 0.868 [0.819 to 0.912] | 85%  |
| 2-year survival rate                  | 34              | 1624       | 0.717 [0.636 to 0.791] | 91%  |
| 3-year survival rate                  | 39              | 2085       | 0.629 [0.543 to 0.712] | 93%  |
| 5-year survival rate                  | 48              | 3217       | 0.449 [0.374 to 0.526] | 94%  |

Abbreviations: LC = lung cancer; sMPLC = synchronous multiple primary lung cancer.
Convincingly, a significant increasing trend of proportion of sMPLC over time was found in our study, and subgroup analysis according to publication time also consolidates this finding. Additionally, we provided a precise proportion of sMPLC in lung cancer. We also found that the average age of 63.4 years and female percentage of 36.7% were similar to patients with single lung cancer. Though it is quite difficult to differentiate sMPLC from intrapulmonary...
metastases and inflammatory nodules by tumor number, histology, and tumor location, it is still worth to explore their effect on the prognosis of sMPLC.

Database study involving multiple centers reported that postoperative mortality of lung cancer was 2.2%. With the early stage cases increased, appropriate preoperative evaluation and perioperative management, the mortality was decreased over time. In sMPLC, we also found a decreased trend of postoperative mortality over time, with a pooled estimated incidence of 1.4%, which was lower than the single primary lung cancer. This could be explained by the small sample size, more prudent surgery selection, and lung-preserved procedure preferred in our study. According to the eighth edition of the TNM classification for lung cancer, the estimated survival rates in patients with sMPLC were similar to IIB-IIIA stage, with 2- and 5-year survival rate of 71.6% and 44.9%. The widely accepted sMPLC staging method is according to the location of separate tumor nodules relative to the main tumor, classifying as T3 in the same lobe, T4 in ipsilateral different lobe, and M1a in contralateral lobe. A study confirmed the applicability of this classification method for intrapulmonary metastases, with similar OS
However, whether this classification could predict the prognosis of sMPLC remains unclear, and differentiating sMPLC from intrapulmonary metastases is still a big challenge.

Another proposed classification system by IASLC stated that all sMPLC nodules should be staged separately and the highest T category with the number of tumors in parenthesis (e.g., T2(m)NxMx) should be used to indicate the T stage of disease. This staging method seems to consider the disease status comprehensively with all tumors involved, but it cannot reach a specific TNM category to predict the prognosis. AJCC specified that this staging method could only be used in patients with the same histology. The current contradiction and controversy for sMPLC staging indicates that an appropriate classification system is still required to be established.

In our study, we explored the potential clinical prognostic factors. Consistently with NSCLC, the negative association between long-term survival and elder age and male gender in sMPLC were identified in our study. Improved prognosis in female might be explained by the younger age distribution, more histologic subtype of adenocarcinoma, and hormonal factors. It is an undisputed fact that smoking causes lung cancer and negatively affects the prognosis. More than 60 carcinogens in smoking could directly damage and mutate DNA, while smoking cessation could promote the replenishment of bronchial epithelium with cells and regenerative capacity of the lungs. Owing to tobacco control, epidemiological

| Subgroup                                    | Hazard Ratio with 95%CI                  | Studies | $I^2$ | $P$   |
|---------------------------------------------|-----------------------------------------|---------|-------|-------|
| Age                                         |                                         |         |       |       |
| Older vs. Young                             | 1.895 [1.405 to 2.557]                  | 5       | 0%    | <0.0001|
| Gender                                      |                                         |         |       |       |
| Male vs. Female                             | 2.162 [1.705 to 2.742]                  | 7       | 0%    | <0.0001|
| Smoking status                              |                                         |         |       |       |
| Smoker vs. Never smoker                     | 3.033 [2.061 to 4.464]                  | 5       | 10%   | <0.0001|
| FEV1                                        |                                         |         |       |       |
| High vs. Low                                | 0.597 [0.305 to 1.169]                  | 3       | 77%   | 0.1323 |
| Number of tumors                            |                                         |         |       |       |
| More than 3 tumors vs. 2 tumors             | 1.618 [0.267 to 9.812]                  | 2       | 74%   | 0.6009 |
| Tumor location                              |                                         |         |       |       |
| Bilateral vs. Same lobe                     | 1.284 [0.757 to 2.176]                  | 3       | 0%    | 0.3539 |
| Ipsilateral different lobes vs. Same lobe   | 1.658 [0.952 to 2.885]                  | 2       | 0%    | 0.0738 |
| Bilateral vs. Unilateral                    | 1.040 [0.595 to 1.820]                  | 4       | 53%   | 0.8896 |
| Largest tumor size                          |                                         |         |       |       |
| $>$2cm vs. $\leq$2cm                       | 5.059 [2.957 to 8.654]                 | 2       | 11%   | <0.0001|
| $>$3cm vs. $\leq$3cm                       | 2.722 [1.201 to 6.173]                 | 2       | 0%    | 0.0165 |
| Per cm increase                             | 1.139 [0.1061 to 1.222]                | 2       | 0%    | 0.0003 |
| Sum of tumors size                          |                                         |         |       |       |
| $>$3cm vs. $\leq$3cm                       | 8.419 [2.497 to 28.389]                | 1       | ---   | 0.0006 |
| Per cm increase                             | 1.150 [0.105 to 1.260]                 | 1       | ---   | 0.0027 |
| Surgery methods                             |                                         |         |       |       |
| Limited vs. Anatomical                      | 1.357 [0.1047 to 1.759]                | 9       | 24%   | 0.021  |
| Pneumonectomy vs. No                       | 2.643 [1.539 to 4.541]                | 6       | 63%   | 0.0004 |
| Tumor histology                             |                                         |         |       |       |
| Different vs. Same                         | 1.636 [0.706 to 3.790]                 | 5       | 83%   | 0.2509 |
| Lymph node metastasis                       |                                         |         |       |       |
| N1 vs. N0                                  | 2.049 [1.253 to 3.349]                 | 2       | 0%    | 0.0042 |
| N2 vs. N0                                  | 3.131 [1.148 to 8.543]                 | 2       | 74%   | 0.0258 |
| N1+ vs. N0                                 | 2.906 [1.977 to 4.272]                 | 8       | 43%   | <0.0001|
| Yes (N1, N2, and N1+) vs. N0               | 2.717 [2.056 to 3.618]                 | 10      | 38%   | <0.0001|
| Postoperative adjuvant therapy              |                                         |         |       |       |
| Yes vs. No                                  | 1.004 [0.502 to 2.007]                 | 4       | 55%   | 0.9918 |

**FIGURE 4** Additional analysis of overall survival according to various clinical parameters. All meta-analyses were performed with random-effects model. HR more than 1 means the results favor reference group.
studies reported that lung cancer mortality had considerably decreased in United States. In sMPLC, the negative effect of smoking on prognosis and the beneficial effect of smoking cessation also verified. FEV1 is an important preoperative evaluation item for surgical method selection and prediction of postoperative clinical outcomes, and patients with high FEV1 could receive more treatment ways and exhibit better prognosis. The role of FEV1 in sMPLC prognosis is more significant, since completed resection of tumors necessitate pulmonary function capacity.

T descriptor is a mandatory classification parameter of the TNM staging system and major prognostic factor in lung cancer. The size of the primary tumor and its invasion to nearby tissue determined T category. Consistently, the negative association between the largest tumor size and prognosis was observed in sMPLC, and the sum of tumors’ sizes also had a significant impact on sMPLC prognosis. While whether the largest tumor size or sum of tumors’ sizes should be chosen as a candidate for staging remains to be explored. Lymph node metastasis, another major prognostic factor in lung cancer, was also found to be an indicator of poor prognosis in sMPLC. No significant difference in prognosis was detected between different number of tumors in sMPLC, indicating lack of evidence supporting them as a staging classification parameter. The poor prognosis trend among sMPLC patients with different histology was observed in our study and it was consistent with a previous pooled analysis of six studies. Should histology type be considered in staging sMPLC remains unclear. No association between tumor location and prognosis of sMPLC in our study, while this pooled analysis demonstrated that patients with unilateral tumor location had a poorer prognosis than those with bilateral disease. This inconsistent might be attributed to the small sample size in the pooled analysis. However, both findings suggest that current staging classification according to the location of separate tumor nodules relative to the main tumor is not appropriate for sMPLC. Further studies are still needed to assess their prognostic effects since sample sizes and sparse studies included in our study.

Though surgical resection has been considered as the first-choice treatments for sMPLC, the surgical method and its effect on prognosis remain controversial. According to the included studies, lobectomy, bi-lobectomy, and pneumonectomy with lymphadenectomy were regarded as anatomical resection and at least one sublobar resection involved was treated as limited resection. A meta-analysis showed that limited resection has a slightly poor trend of OS in sMPLC by comparison of anatomical resection, without a statistical significance. While in our study, though most of our included studies found no significant difference in prognosis, the pooled estimate from nine studies indicated that patients received anatomical resection has a significantly better prognosis than limited resection. One study focusing on both synchronous and metachronous MPLC patients also confirmed the better OS advantage of anatomical resection than sublobar resection. However, anatomical resection for all tumor nodules is impractical for patients with limited cardiorespiratory status, and sublobar resection is also a valid option. While it also demonstrated that anatomical segmentectomy could confer a comparable survival benefit with lobectomy and a better prognosis than nonanatomical resections and. In another study, sublobar resection for at least one lesion is advised for patients with sMPLC to preserve cardiorespiratory status. Additionally, pneumonectomy is associated with a greater operative risk than lobectomy and sublobar resection, and poor pulmonary function induced by pneumonectomy also facilitates a poor prognosis. However, pneumonectomy, as a bailout procedure, is inevitable even in stage I single lung cancer for intraoperative safe dissection and tumor mass, large lymph nodes, or cancerous mass near to hilum. Considering the cardiorespiratory status, operative risk, postoperative pulmonary function, and long-term prognosis, our finding supports that anatomical resection should be preferred for sMPLC with adequate pulmonary reserve and pneumonectomy should be always avoided unless absolutely inevitable. For patients with limited pulmonary function, lobectomy with sublobar resection or only sublobar resections are also valid options, and anatomical segmentectomy is preferred in sublobar resection. Limitations should be addressed. First, meta-analysis for survival rates was based on the presupposition of no loss to follow-up. However, we also used the effect size of HR to analyze prognosis and reached consistent results. Second, substantial heterogeneity and publication bias were observed in our meta-analysis. High heterogeneity and publication bias are frequent in meta-analysis for proportion; thus, subgroup analysis and sensitivity analyses were performed to confirm the stability of the pooled estimates and explore the source of heterogeneity. Though the substantial heterogeneity and publication bias could not be explained by the variables inspected, subgroup analysis, sensitivity analyses, and additional analysis confirmed the stability of pooled results. The heterogeneity and publication bias might be associated with study populations, diagnostic equipment, and study period. Third, though 52 studies included, the overall sample size is still small and effect of clinical parameters on prognosis still remains to be explored.

5 | CONCLUSION

There are increasing trends of proportion of sMPLC in lung cancer, with a summary estimate of 2.0%. The 5-year survival rate was 44.9%, and postoperative mortality was
1.4% with a decreasing trend over time. Lobectomy should be preferred for sMPLC, while pneumonectomy should be always avoided. Additionally, lobectomy with sublobar resection or only sublobar resections are also valid options, especially for patients with limited pulmonary function. Age, gender, FEV1, smoking, tumor size, and lymph node status are important prognostic factors for patients with sMPLC after surgery. Considering the heterogeneity and publication bias, the findings should be treated with caution. Further studies are needed to further analyze the clinical prognostic factors to establish a well-predictive staging system for prognosis.

CONFLICT OF INTEREST
The authors declare no competing interests.

ETHICAL APPROVAL
Since all analyses are based on previous published studies, thus, no ethical approval and patient consent are required.

DATA AVAILABILITY STATEMENT
The data used to support the findings of this study are all available in the Data S1.

ORCID
Hongtao Tie https://orcid.org/0000-0003-1058-6407

REFERENCES
1. Beyreuther H. Multiplicität von carcinomen bei einem fall von sog. “Schneeberger” lungenkrebs mit tuberkulose. Virchows Archiv Pathol Anat Physiol Klin Med. 1924;250(1):230-243.
2. Adebonojo SA, Moritz DM, Danby CA. The results of modern surgical therapy for multiple primary lung cancers. Chest. 1997;112(3):693-701.
3. Andriolo LG, Bugana A, Di Chiara F, et al. Surgical results for multiple primary lung cancers. Eur Surg Res. 2012;49(3-4):132.
4. Angeletti CA, Mussi A, Janni A, et al. Second primary lung cancer and relapse: treatment and follow-up. Eur J Cardiothorac Surg. 1995;9(11):607-611.
5. Antkli T, Schaefer RF, Rutherford JE, Read RC. Second primary lung cancer. Ann Thorac Surg. 1995;59(4):863-866.
6. Aziz TM, Saad RA, Glasser J, Jilaihawi AN, Prakash D. The management of second primary lung cancers. A single centre experience in 15 years. Eur J Cardiothorac Surg. 2002;21(3):527-533.
7. Bae MK, Byun CS, Lee CY, et al. Clinical outcomes and prognostic factors for surgically resected second primary lung cancer. Thorac Cardiovasc Surg. 2012;60(8):525-532.
8. Chang YL, Wu CT, Lee YC. Surgical treatment of synchronous multiple primary lung cancers: experience of 92 patients. J Thorac Cardiovasc Surg. 2007;134(3):630-637.
9. Chen K, Wang X, Yang F, et al. Clinical features and treatment outcome of multiple primary lung cancer patients with different imaging performance. Zhonghua Wai Ke Za Zhi. 2015;53(10):731-736.
10. Cheng H, Lei BF, Peng PJ, Lin YJ, Wang XJ. Histologic lung cancer subtype differentiates synchronous multiple primary lung adenocarcinomas from intrapulmonary metastases. J Surg Res. 2017;211:215-222.
11. De Leyn P, Moons J, Vansteenkiste J, et al. Survival after resection of synchronous bilateral lung cancer. Eur J Cardiothorac Surg. 2008;34(6):1215-1222.
12. Deschamps C, Pairolero PC, Trastek VF, Payne WS. Multiple primary lung cancers. Results of surgical treatment. J Thorac Cardiovasc Surg. 1990;99(5):769-778.
13. Fabian T, Bryant AS, Mouhlas AL, Federico RJ. Survival after resection of synchronous non-small cell lung cancer. J Thorac Cardiovasc Surg. 2011;142(3):547-553.
14. Feng FY, Zhang DC, Liu XY, Wang YG, Mao YS. Surgical treatment and prognosis of synchronous double primary lung cancer: a report of 31 cases. Ai Zhong. 2005;24(2):215-218.
15. Finley DJ, Yoshizawa A, Travis W, et al. Predictors of outcomes after surgical treatment of synchronous primary lung cancers. J Thorac Oncol. 2010;5(2):197-205.
16. Guo H, Mao F, Zhang H, Qiu Y, Shen-Ty Y. Analysis on the prognostic and survival factors of synchronous multiple primary lung cancer. Zhongguo Fei Ai Za Zhi. 2017;20(1):21-27.
17. Hardavella G, Karampinis I, Mpairaktari A, Aravantinos G, Anastasiou N. Synchronous primary lung cancers; a clinical challenge in modern thoracic oncology. Eur Respir J. 2018;52.
18. Hsu H-H, Ko K-H, Chou Y-C, et al. SUVmax and tumor size predict synchronous multiple primary lung cancers. Medicine (Baltimore). 2016;95(6):e2351.
19. Ishikawa Y, Nakayama H, Ito H, et al. Surgical treatment for synchronous primary lung adenocarcinomas. Ann Thorac Surg. 2014;98(6):1983-1988.
20. Jung EJ, Lee JH, Jeon K, et al. Treatment outcomes for patients with synchronous multiple primary non-small cell lung cancer. Lung Cancer. 2011;73(2):237-242.
21. Kocaturk CI, Gunluoglu MZ, Cansever L, et al. Survival and prognostic factors in surgically resected synchronous multiple primary lung cancers. Eur J Cardiothorac Surg. 2011;39(2):160-166.
22. Li F, Shao K, He J. The outcome of surgical therapy for double primary lung cancer. Zhonghua Wai Ke Za Zhi. 2011;49(6):535-538.
23. Li J, Yang X, Xia T, Guan Y, Zhong N. Stage I synchronous multiple primary non-small cell lung cancer: CT findings and the effect of TNM staging with the 7th and 8th editions on prognosis. J Thorac Dis. 2017;9(12):5355-5344.
24. Lin MW, Wu CT, Kuo SW, Chang YL, Yang PC. Clinicopathology and genetic profile of synchronous multiple small adenocarcinomas: implication for surgical treatment of an uncommon lung malignancy. Ann Surg Oncol. 2014;21(8):2555-2562.
25. Liu M, He W, Yang J, Jiang G. Surgical treatment of synchronous multiple primary lung cancers. Results of surgical treatment. J Thorac Oncol. 2014;98(6):1917-2004.
26. Liu Y, Yang P. The prognosticator for synchronous multiple primary lung cancer: a retrospective analysis of 122 patients. J Thorac Dis. 2016;8(6):1197-1204.
27. Lv J, Zhu D, Wang X, Shen Q, Rao Q, Zhou X. The value of prognostic factors for survival in synchronous multifocal lung cancer: a retrospective analysis of 164 patients. Ann Thorac Surg. 2018;105(3):930-936.
28. Mun M, Kohno T. Single-stage surgical treatment of synchronous bilateral multiple lung cancers. Ann Thorac Surg. 2007;83(3):1146-1151.
29. Okada M, Tsubota N, Yoshimura M, Miyamoto Y. Operative approach for multiple primary lung carcinomas. *J Thorac Cardiovasc Surg*. 1998;115(4):836-840.

30. Peng Y, Ren W, Wang H, Li M, Feng Z, Peng Z. Surgical treatment is an effective approach for patients with synchronous multiple primary lung cancers. *J Cancer Res Ther*. 2017;13(4):702-706.

31. Pommier RF, Vetto JT, Lee JT, Johnston KM. Synchronous non-small cell lung cancers. *Am J Surg*. 1996;171(5):521-524.

32. Rea F, Zuin A, Callegaro D, Bortolotti L, Guanella G, Sartori F. Surgical results for multiple primary lung cancers. *Eur J Cardiothorac Surg*. 2001;20(3):489-495.

33. Ribet M, Dambron P. Multiple primary lung cancers. *Eur J Cardiothorac Surg*. 1995;9(5):231-236.

34. Riquet M, Cazes A, Pfeuty K, et al. Multiple lung cancers prognosis: what about histology? *Ann Thorac Surg*. 2008;86(3):921-926.

35. Rosengart TK, Martini N, Ghosn P, Burt M. Multiple primary lung cancer: an increasing clinical occurrence requiring multiple synchronous lung cancers. *World J Surg*. 2010;34(2):169-175.

36. Rostad H, Strand TE, Naalsund A, Norstein J. Resected synchronous multiple primary lung cancers. *Ann Thorac Surg*. 2017;151(5):521-524.

37. Shah AA, Barfield ME, Kelsey CR, et al. Outcomes after surgical management of synchronous bilateral primary lung cancers. *Ann Thorac Surg*. 2012;93(4):1055-1060.

38. Takamochi K, Oh S, Matsuoka J, Suzuki K. Clonality status of multifocal lung adenocarcinomas based on the mutation patterns of EGFR and K-ras. *Lung Cancer*. 2012;75(3):313-320.

39. Tanvetyanon T, Robinson L, Sommers KE, et al. Relationship between tumor size and survival among patients with resection of multiple synchronous lung cancers. *J Thorac Oncol*. 2010;5(7):1018-1024.

40. Trouse D, Barlesi F, Loundou A, et al. Synchronous multiple primary lung cancer: an increasing clinical occurrence requiring multidisciplinary management. *J Thorac Cardiovasc Surg*. 2007;133(5):1193-1200.

41. Tsunekawa Y, Matsumoto I, Tamura M, et al. The results of therapy for bilateral multiple primary lung cancers: 30 years experience in a single centre. *Eur J Surg Oncol*. 2004;30(7):781-785.

42. Tung YW, Hsu CP, Shai SE, Hsia JY, Yang SS, Chen CY. Surgical feasibility of ipsilateral multifocal non-small cell lung cancer in different lobes: excellent survival in node-negative subgroup. *Eur J Cardiothorac Surg*. 2003;24(6):1008-1012.

43. van Rens MTM, Zanen P, Brutel de la Rivière A, Elbers HRJ, van Swieten HA, van den Bosch JMM. Survival in synchronous bilateral multiple primary lung cancers: similar to the stage-matched solitary primary lung cancers? *Ann Thorac Surg*. 2013;96(6):1966-1974.

44. Vansteenkiste JF, De Belie B, Deneffe GJ, et al. Practical analysis of observational studies in epidemiology: a proposal for reporting. *JAMA*. 2000;283(15):2008-2012.

45. Verhagen AF, Tavilla G, van de Wal HJ, Cox AL, Lacquet LK. Multiple primary lung cancers. *Thorac Cardiovasc Surg*. 1994;42(1):40-44.

46. Voltolini L, Rapicetta C, Luzzi L, et al. Surgical treatment of synchronous multiple lung cancer located in a different lobe or lung: high survival in node-negative subgroup. *Eur J Cardiothorac Surg*. 2010;37(5):1198-1204.

47. Wang S, Wang C. Clinical analysis of 23 cases of double primary lung cancer. *Chin J Clin Oncol*. 2008;35(5):259-261.

48. Wang Y, Wang L, Zhang D. Diagnosis and surgical treatment of double primary lung cancer. *Zhonghua Zhong Liu Za Zhi*. 2001;23(5):428-430.

49. Wu SC, Lin ZQ, Xu CW, Koo KS, Huang OL, Xie DQ. Multiple primary lung cancers. *Chest*. 1987;92(5):892-896.

50. Xiao F, Liu D, Guo Y, et al. Survival rate and prognostic factors of surgically resected clinically synchronous multiple primary non-small cell lung cancer and further differentiation from intrapulmonary metastasis. *J Thorac Dis*. 2017;9(4):990-1001.

51. Yu YC, Hsu PK, Yeh YC, et al. Surgical results of synchronous multiple primary lung cancers: similar to the stage-matched solitary primary lung cancers? *Ann Thorac Surg*. 2013;96(6):1966-1974.

52. Zeng Z, Gao S, Mao Y, et al. Surgical outcomes of synchronous multiple primary non-small cell lung cancers. *Sci Rep*. 2016;6:23252.

53. Zuin A, Andriolo LG, Marulli G, et al. Is lobectomy really more effective than sublobar resection in the surgical treatment of second primary lung cancer? *Eur J Cardiothorac Surg*. 2013;44(2):e120-e125.

54. Li M, Wan Y, Zhang L, et al. Synchronous multiple lung cancers presenting as multifocal pure ground glass nodules: are whole-body positron emission tomography/computed tomography and brain enhanced magnetic resonance imaging necessary? *Transl Lung Cancer Res*. 2019;8(5):649-657.

55. Rami-Porta R, Ball D, Crowley J, et al. The IASLC lung cancer staging project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. *J Thorac Oncol*. 2007;2(7):593-602.

56. Asamura H. Multiple primary cancers or multiple metastases, that is the question. *J Thorac Oncol*. 2010;5(7):930-931.

57. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ*. 2009;339:b2700.

58. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. *Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA*. 2000;283(15):2008-2012.

59. Rotenstein LS, Ramos MA, Torre M, et al. Prevalence of depression, depressive symptoms, and suicidal ideation among medical students: a systematic review and meta-analysis. *JAMA*. 2016;316(21):2214-2236.

60. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. *Eur J Epidemiol*. 2010;25(9):603-605.

61. Rucker G, Schwarzer G, Carpenter J, Olkin I. Why add anything to nothing? The arcsine difference as a measure of treatment effect in meta-analysis with zero cells. *Stat Med*. 2009;28(5):721-738.

62. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ*. 2003;327(7414):557-560.

63. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ*. 2001;324(7344):55-61.

64. Chen C, Huang X, Peng M, Liu W, Yu F, Wang X. Multiple primary lung cancer: a rising challenge. *Eur J Epidemiol*. 2019;34(6):523-S536.

65. Gunn J, Valo J, Sipila J, Rautava P, Sihvo E, Kyto V. Trends and results of lung cancer surgery in Finland between 2004 and 2014. *Eur J Cardiothorac Surg*. 2018;54(1):127-133.
66. Hirsch FR, Scagliotti GV, Mulshine JL, et al. Lung cancer: current therapies and new targeted treatments. *Lancet*. 2017;389(10066):299-311.

67. Kozower BD, Sheng S, O’Brien SM, et al. STS database risk models: predictors of mortality and major morbidity for lung cancer resection. *Ann Thorac Surg*. 2010;90(3):875-883.

68. Watanabe S, Asamura H, Suzuki K, Tsuchiya R. Recent results of postoperative mortality for surgical resections in lung cancer. *Ann Thorac Surg*. 2004;78(3):999-1002.

69. Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. *J Thorac Oncol*. 2016;11(1):39-51.

70. Detterbeck FC, Bolejack V, Arenberg DA, et al. The IASLC lung cancer staging project: background data and proposals for the classification of lung cancer with separate tumor nodules in the forthcoming eighth edition of the TNM classification for lung cancer. *J Thorac Oncol*. 2016;11(5):681-692.

71. Detterbeck FC, Nicholson AG, Franklin WA, et al. The IASLC lung cancer staging project: summary of proposals for revisions of the classification of lung cancers with multiple pulmonary sites of involvement in the forthcoming eighth edition of the TNM classification. *J Thorac Oncol*. 2016;11(5):639-650.

72. Detterbeck FC, Postmus PE, Tanoue LT. The stage classification of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest*. 2013;143(5 Suppl):e191S-e210S.

73. Molinier O, Goupil F, Debieuvre D, et al. Five-year survival and prognostic factors according to histology in 6101 non-small-cell lung cancer patients. *Respir Med Res*. 2019;77:46-54.

74. Fu JB, Kau TY, Severson RK, Kalemkerian GP. Lung cancer in women: analysis of the national surveillance, epidemiology, and end results database. *Chest*. 2005;127(3):768-777.

75. Yoshida K, Gowers KHC, Lee-Six H, et al. Tobacco smoking and somatic mutations in human bronchial epithelium. *Nature*. 2020;578(7794):266-272.

76. Jeon J, Holford TR, Levy DT, et al. Smoking and lung cancer mortality in the United States from 2015 to 2065: a comparative modeling approach. *Ann Intern Med*. 2018;169(10):684-693.

77. Brunelli A, Kim AW, Berger KJ, Addirizzo-Harris DJ. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest*. 2013;143(5 Suppl):e166S-e190S.

78. Gajra A, Newman N, Gamble GP, Kohman LJ, Graziano SL. Effect of number of lymph nodes sampled on outcome in patients with stage I non-small-cell lung cancer. *J Clin Oncol*. 2003;21(6):1029-1034.

79. Tanvetyanon T, Finley DJ, Fabian T, et al. Prognostic factors for survival after complete resections of synchronous lung cancers in multiple lobes: pooled analysis based on individual patient data. *Ann Oncol*. 2013;24(4):889-894.

80. Waller DA. Surgical management of lung cancer with multiple lesions: implication of the new recommendations of the 8(th) edition of the TNM classification for lung cancer. *J Thorac Dis*. 2018;10(Suppl 22):S2686-S2691.

81. Chen T-F, Xie C-Y, Rao B-Y, et al. Surgical treatment to multiple primary lung cancer patients: a systematic review and meta-analysis. *BMC Surg*. 2019;19(1):185.

82. Toufektzian L, Attia R, Veres L. Does the extent of resection affect survival in patients with synchronous multiple primary lung cancers undergoing curative surgery? *Interact Cardiovasc Thorac Surg*. 2014;19(6):1059-1064.

83. Alexiou C, Beggs D, Onyeaka P, et al. Pneumonectomy for stage I (T1N0 and T2N0) nonsmall cell lung cancer has potent, adverse impact on survival. *Ann Thorac Surg*. 2003;76(4):1023-1028.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section.

**How to cite this article:** Tie H, Luo J, Shi R, Li Z, Chen D, Wu Q. Characteristics and prognosis of synchronous multiple primary lung cancer after surgical treatment: A systematic review and meta-analysis of current evidence. *Cancer Med*. 2021;10:507–520. [https://doi.org/10.1002/cam4.3614](https://doi.org/10.1002/cam4.3614)